Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Bratton
Selection of Quantitative Decision‐Making Criteria Using Weighted Decision Error Rates
Conflicts of Interest D.B. owns shares in GSK. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Supporting Information Filename Description pst70057-sup-0001-supinfo.docxWord 2007 document , 70 KB Appendix S1: Supporting Information. References 1, , , and , “Decision-Making in Early Clinical Drug Development,” Pharmaceutical Statistics 15, no. 3 (2016): 255–263.
Facilities for optimizing and designing multiarm multistage (MAMS) randomized controlled trials with binary outcomes
Facilities for optimizing and designing multiarm multistage (MAMS) randomized controlled trials with binary outcomes Autores: Babak Choodari-Oskooei, Daniel J. Bratton, Mahesh K. B. Parmar Localización: The Stata journal, ISSN 1536-867X, Vol. 23, Nº. 3, 2023, págs. 774-798 Idioma: inglés Texto completo no disponible (Saber más ...) Resumen We introduce two commands, nstagebin and nstagebinopt, that can be used to facilitate the design of multiarm multistage (MAMS) trials with binary outcomes.
Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]
The recently published article ‘ Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma’ by Eric Bateman et al. presents an indirect treatment comparison (ITC) of dupilumab and other biologics in patients with uncontrolled asthma, based on analysis of subgroups from the respective randomized controlled trials (RCTs) [ ].
Adding new experimental arms to randomised clinical trials: Impact on error rates
Introduction Many recent developments in clinical trials are aimed at speeding up research by making better use of resources. Phase III clinical trials can take several years to complete in many disease areas, requiring considerable resources. During this time, a promising new treatment which needs to be tested may emerge.
Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
LETTER TO THE EDITOR Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use Frank C. Albers Corresponding Author E-mail address: frank-c.albers@t-online.de Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA Affiliation at time of the analysis. Frank C Albers’ current affiliation is Avillion US Inc. Corresponding author: Name: Frank C. Albers Address: 103 Glade Street, Chapel Hill, NC 27516.
Reply
Bourdin and Molinari1 suggest that methodological issues may have impacted the robustness and replicability of results described in our article2 that evaluated the relative efficacy of mepolizumab, benralizumab, and reslizumab through an indirect treatment comparison using the Bucher method.3 Specifically, the authors propose that matching-adjusted indirect comparison (MAIC),4 which was recently used in a study by Bourdin et al,5 is more appropriate for accounting for differences in effect...
The impact of obstructive sleep apnoea on the aorta
AbstractObstructive sleep apnoea (OSA) has been shown to be a causal factor in the pathogenesis of vascular dysfunction and hypertension, conditions which can promote dilation and subsequent aortic dissection and rupture.
Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study
Background Patients with the connective tissue disorder Ehlers-Danlos syndrome (EDS) often suffer from fatigue, excessive daytime sleepiness and impaired quality of life. Obstructive sleep apnoea (OSA) may be an underlying cause for these symptoms but its prevalence in this population is unclear.
Reappraisal of the clinical effect of mepolizumab - Authors' reply
In reference to the letter by Brian J Lipworth and Sunny Jabbal on our MUSCA publication, 1 we would like to respond to the points presented. They state that the St George's Respiratory Questionnaire (SGRQ) is not suitable for assessing health-related quality of life (HRQOL) in asthma.
Effects of CPAP and MADs on health-related quality of life in OSA: a systematic review and meta-analysis
Background Untreated obstructive sleep apnea (OSA) is associated with impaired health-related quality of life (QoL) and excessive daytime sleepiness which have been shown to improve with treatment. The aim was to compare the effects of continuous positive airway pressure (CPAP) and mandibular advancement devices (MAD) on health-related QoL in OSA. Methods MEDLINE and Cochrane Library were searched up to November 2015.
Obstructive sleep apnoea and quality of life in Ehlers-Danlos syndrome: a parallel cohort study
Background Patients with the connective tissue disorder Ehlers-Danlos syndrome (EDS) often suffer from fatigue, excessive daytime sleepiness and impaired quality of life. Obstructive sleep apnoea (OSA) may be an underlying cause for these symptoms but its prevalence in this population is unclear.
Obstructive sleep apnea in Ehlers-Danlos syndrome. A prospective case-control study
AbstractThe Ehlers-Danlos syndrome (EDS) is an inherited heterogeneous group of connective tissue disorders, affecting tissue fragility, blood vessels, and other organs. EDS patients are known to suffer from significant sleep problems and excessive daytime sleepiness.
ECG risk markers for atrial fibrillation and sudden cardiac death in minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised trial
Results Participants were primarily men (83%). Mean age was 57.8 (7.2) and mean ODI (Oxygen Desaturation Index) at baseline was 13.1/h (12.3). Full 12-lead ECG data was available in 250 patients. Mean (SD) baseline intervals of P-wave duration, P-wave dispersion, QT c interval, QT dispersion, TpTe and TpTe/QT ratio in ms were 87.4 (8.3), 42.3 (11.9), 397.8 (22.7), 43.1 (16.7), 73.5 (13.7) and 0.19 (0.0), respectively. No treatment effect of CPAP on risk markers for AF and SCD was found.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack